We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
UK biotech racing to keep antibody up to date with latest variants
Agreement is one of several announced as major healthcare conference begins in San Francisco
Daiichi Sankyo and AstraZeneca’s Enhertu could double time patients can live without their condition progressing
Success in battle against Covid does not ensure success against tumours, but should narrow the odds
Chief commercial officer Luke Miels looking at targets worth up to $2.5bn
Eli Lilly, Amgen, Pfizer and Regeneron follow Novo Nordisk into obesity treatments worth billions
From obesity drugs to cancer treatments, this year should be remembered for pharmaceutical advances
Former Johnson & Johnson executive ‘on the look out’ for rivals amid biotech sell-off
CSL’s $3.5mn single-dose treatment for haemophilia sparks debate over how to pay for revolutionary drugs
Study suggests combination with Merck immunotherapy drug reduces risk of death in high-risk patients
Dementia drug development, diagnostics and delivery still require much more investment
Japanese company refuses to rule out possibility treatment contributed to brain bleeds
Shares fall 11% following two patient deaths in trials of lecanemab
The early death of an Alzheimer’s patient taking part in lecanemab trials sent shares down
Results from UK-wide trials on anticoagulant Apixaban set to change protocols around the world
The FT examines the causes and effects of an increasing global resistance to antibiotics: from the pressures doctors are under to prescribe them, to what new treatments are currently in the pipeline, as well as what role can the consumer play in reducing antibiotic use in the food chain
Eli Lilly seeks approval for weight loss medication as Novo Nordisk battles supply crunch for Wegovy
Two studies of antibody treatment gantenerumab fail to slow decline in people with early-stage disease
Brash new investors are clashing with the pioneers of mind-altering drug therapies
UK-led research paves way for regulatory approval of active ingredient psilocybin
Verge says ALS therapy is one of the first to be developed by a tech-enabled platform
Iranian-American artist Shirin Neshat discusses the protests in Iran. Then, we explore the future of animal testing in medicine
Drugmaker says new RSV shot appears more effective than rival Pfizer’s candidate
Study of Eisai treatment will be one of last chances to prove amyloid hypothesis, say experts
Pharmaceutical companies have taken aim at group whose research helped spark a wave of lawsuits
UK Edition
